GammaTile by GT Medical Technologies, Inc.

GammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors.

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Strong data from the ROADS clinical trial highlight the potential of GammaTile® cesium-131 collagen tile-based radiation therapy (TBRT) to improve outcomes for patients with brain metastases requiring surgery.

In the multicenter Phase 3 study, immediate placement of tile-based radiation during surgery resulted in significantly lower rates of tumor regrowth, a greater likelihood of living longer without recurrence, and significantly improved overall survival compared to standard of care, without increased side effects.

These findings, published as a Rapid Communication in the Journal of Clinical Oncology, reinforce the value of delivering targeted radiation therapy at the time of surgery. Based on the results, the study authors conclude that GammaTile should be considered a standard-of-care option for patients with newly diagnosed operable brain metastases.

Read the press release: https://t.co/4dtHDzQyVa

#ROADSTrial #GammaTile #JCO @JCO_ASCO

See full prescribing information at https://t.co/MKevTlz0mQ

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

“Intraoperative radiation tile slashes recurrence rates while improving survival in brain cancer patients,” reads the headline of a @RadiologyBiz article on the ROADS phase 3 trial results, which compared GammaTile with standard post-operative stereotactic radiation therapy in 230 patients across 32 centers.

Read the article: https://t.co/xnd032TQYV

See full prescribing information at https://t.co/VUlzltk7qQ

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

@NeuroOnc is quickly approaching, taking place November 12-15. Stop by the GammaTile booth to learn more about GammaTile and see the latest data.

Explore the GammaTile schedule at #SNO2026: https://t.co/otCvbcIHp8

See full prescribing information at https://t.co/vNDcAO6R89

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

The evidence is in: GammaTile demonstrated superiority to the standard of care in the ROADS Phase 3 trial results. Its superior efficacy did not come at the expense of increased toxicity.(1)

Read the publication: https://t.co/7cmzCD4obF

Reference: Weinberg JS, Imber BS, DiNapoli V, et al. J Clin Oncol. 2026.

See full prescribing information at https://t.co/03MZ0bbbwy

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

It’s not too late to reserve your spot for tonight’s GammaTile Clinical Dinner Symposium at #2026CNS to learn more about the latest GammaTile data.

Reserve Your Spot: https://t.co/1m1PUPNDAR

See full prescribing information at https://t.co/xaYrKormPG

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

“A new radiation implant placed during surgery for brain metastases nearly stopped tumors from returning and doubled survival, a new study found,” reads a @cure_today article about the ROADS phase 3 trial results published in the Journal of Clinical Oncology (@JCO_ASCO) last month.

Read the article: https://t.co/bSotlY2XU9

See full prescribing information at https://t.co/eGZmmAPbxe

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

GammaTile is proven superior to standard of care in the ROADS Phase 3 trial results, published in the Journal of Clinical Oncology.(1)

Compared to standard of care, GammaTile demonstrated superior time to surgical bed recurrence, superior surgical bed recurrence-free survival, and signficiantly longer overall survival.

Read the publication to learn more: https://t.co/BKjwboLiew

Reference: Weinberg JS, Imber BS, DiNapoli V, et al. J Clin Oncol. 2026.

See full prescribing information at https://t.co/vw5t4rYa9q

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Are you attending #2026CNS next week?

There are limited spots available for our Clinical Dinner Symposium, “The Surgeon’s Role in Radiation Timing: A Neurosurgeon’s Perspective on ROADS,” at 6:00 PM on Monday, November 2nd.

Reserve Your Spot: https://t.co/dbjRWYyPsw

See full prescribing information at https://t.co/5LFCM2bcG6

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Join GammaTile for a clinical lunch symposium, “ROADS Phase 3 Evidence: Published Results and What They Mean for Newly Diagnosed Brain Metastases,” during SYM10A/B: Brain Tumor Update - Malignant and Benign at the Congress of Neurological Surgeons (@CNS_Update) Annual Meeting.

Add to calendar: https://t.co/8TBgLf0nyz

#2026CNS

See full prescribing information at https://t.co/noBmA6lEHe

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

The Phase 3 ROADS Trial findings were recently reported by Nuclio Media, a leading publication dedicated to the business of nuclear medicine.

Read the article:
https://t.co/ojBtnbeuLM

See full prescribing information at https://t.co/axZ1T0b67r

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Close out Day 3 of #2026CNS at our Clinical Dinner Symposium, where you’ll learn more about the latest GammaTile data.

Reserve Your Spot: https://t.co/81gulR7FGs

See full prescribing information at https://t.co/Eura29mlK5

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

We recently welcomed Columbia University Irving Medical Center/NewYork-Presbyterian Hospital as the latest GammaTile Center of Excellence. Neurosurgeon Brian J.A. Gill, MD, shares what this recognition means for the team and their dedication to advancing brain tumor care.

Read the press release: https://t.co/Q4lyxD4p7r

#GammaTileCOE

See full prescribing information at https://t.co/8tJFy8KkqI

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Join GammaTile for a clinical lunch symposium, “ROADS Phase 3 Evidence: Published Results and What They Mean for Newly Diagnosed Brain Metastases,” during SYM10A/B: Brain Tumor Updates - Malignant and Benign at the Congress of Neurological Surgeons (@CNS_Update) Annual Meeting.

Add to calendar: https://t.co/ZEO6fGizmf

See full prescribing information at https://t.co/ZZY42TRgRd

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Hear from radiation oncologist and GammaTile practitioner Dr. Lindsey Sloan on M Health Fairview University of Minnesota Medical Center’s designation as a GammaTile Center of Excellence this past March.

Lindsey Sloan, MD, PhD, is an Associate Professor in Radiation Oncology and a radiobiologist at the Masonic Cancer Center. She leads the Sloan Laboratory within the University of Minnesota Brain Tumor Program and serves on the faculty of the University of Minnesota Medical School.

#GammaTileCOE

See full prescribing information at https://t.co/1s2yvaMSVY

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

Are you attending #2026CNS? Join us at one of our educational events to hear how GammaTile is improving tumor control in operable brain tumors.

Explore the GammaTile schedule: https://t.co/GSPkvd87UZ

See full prescribing information at https://t.co/j6sJrJvXFp

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

GammaTile achieved 98.7% local tumor control by 12 months, compared to 84.6% for standard of care, reducing the risk of local tumor recurrence at 12 months by more than 90% (HR: 0.07, 95% CI: 0.01–0.56; p=0.012)1*

In the manuscript's conclusion, the study authors state that GammaTile should be considered a standard-of-care option for patients with newly diagnosed brain metastases.

Read the publication: https://t.co/XWvibtDZMw

Reference: Weinberg JS, Imber BS, DiNapoli V, et al. J Clin Oncol. 2026.

*Local control calculated as 100% minus the cumulative incidence of surgical bed recurrence (SBR) expressed as a percentage.

See full prescribing information at https://t.co/EmVFOiZAH0

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

At #ASTRO26, we invited attendees for an evening on the waterfront to learn more about the ROADS RCT data and best practices for tile-based radiation therapy integration.

The GammaTile team welcomed Lindsey Sloan, MD, PhD, and M. Sean Peach, MD, PhD, to present how Tile-Based Radiation Therapy (TBRT) with GammaTile is revolutionizing treatment timing and local control by closing the treatment gap.

Thank you to everyone who joined us for an evening of great conversation, and to Drs. Sloan and Peach for sharing their insights. We’re eager to keep the momentum going as we work together to close the treatment gap for patients with operable brain tumors.

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

We are proud to announce Columbia University Irving Medical Center/New York-Presbyterian Hospital as our latest GammaTile Center of Excellence, acknowledging their outstanding clinical expertise in the GammaTile procedure.

The following physicians have received this designation:
- Brian J.A. Gill, MD, Neurological Surgeon
- Michael B. Sisti, MD, Neurological Surgeon
- Tony Wang, MD, Radiation Oncologist

Read the press release: https://t.co/FfRYAriSJa

See full prescribing information at https://t.co/phWzbTWrDf

[GammaTile by GT Medical Technologies, Inc. @GammaTile]

St. Luke's Boise Medical Center has been named our newest GammaTile Center of Excellence, recognizing their expertise in the GammaTile procedure and commitment to advancing brain tumor treatment.

The following physicians have received this designation:
- Edward A. Duckworth, MD
- David P. Bray, MD
- Derek L. Martinez, MD
- Benjamin G. McGahan, MD
- Cameron S. Thorpe, MD
- Tonya L. Kuhn, MD
- Stephen C. Smith, MD
- Timothy E. Sawyer, MD
- Amy Geyer, MS

Read the press release: https://t.co/DcTQ5SU9Zw

#GammaTile #GammaTileCOE

See full prescribing information at https://t.co/oF5XjGZqhK